Search

Displaying results 221 - 230 of 314 in total
  1. Drug

    Fomivirsen

    go.drugbank.com/drugs/DB06759
    ApprovedWithdrawn

    Fomivirsen is a antisense 21 mer phosphorothioate oligonucleotide.

  2. Drug

    Povidone

    go.drugbank.com/drugs/DB11061
    ApprovedInvestigationalWithdrawn

    somewhat controversial, as it was demonstrated in a few clinical studies that the application of the compound in wounds was associated with impaired wound healing, reduced wound strength, or infection in open

  3. Drug

    Doconexent

    go.drugbank.com/drugs/DB03756
    ApprovedInvestigational

    A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic aci...

  4. Drug

    Inaxaplin

    go.drugbank.com/drugs/DB21521
    Investigational

    Inaxaplin is under investigation in clinical trial NCT06794996 (Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease).

  5. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    [A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.

  6. Drug

    Octinoxate

    go.drugbank.com/drugs/DB09496
    ApprovedInvestigational

    Octinoxate is a cinnamate ester and common ingredient in sunscreen and other skin care products to minimize DNA photodamage. It was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun. It is often com...

    Mixtures: LA Mer The SPF 18 Fluid, LA Mer The SPF 18 Fluid TintProducts: LA Mer The Fluid Foundation SPF 15
  7. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  8. Drug

    Muplestim

    go.drugbank.com/drugs/DB12431
    Investigational

    Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL

  9. Drug

    Daptomycin

    go.drugbank.com/drugs/DB00080
    ApprovedInvestigational

    [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]

  10. Drug

    Pocenbrodib

    go.drugbank.com/drugs/DB21616
    Investigational

    Pocenbrodib is under investigation in clinical trial NCT06785636 (Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617).